PAI-1

Plasminogen activator inhibitor-1

PAI-1

Related Products

PAI-1 (Plasminogen activator inhibitor-1, also known as SERPINE1) is a member of serine protease inhibitor (SERPIN) family that acts as the primary inhibitor of two main mammalian plasminogen activators, urinary-type (uPA) and tissue-type (tPA). As the main negative regulator of plasminogen activation, PAI-1 is an essential factor in regulation of the physiological balance between thrombosis and fibrinolysis. PAI-1 is a labile molecule that exists in four different forms: active, latent, cleaved and target bound form.

High PAI-1 levels are associated with many cardiovascular diseases. PAI-1 also plays important roles in cell migration, adhesion, senescence, cancer invasion and tissue remodeling. Moreover, the PAI-1 level was extensively validated as the biological prognostic factor in breast cancer and as a marker of a poor prognosis in other cancers. PAI-1 is also one of the plasma biomarkers associated with nonalcoholic fatty liver disease. These associations have made PAI-1 an attractive pharmaceutical target.

PAI-1 Verwandte Produkte (77)
Recombinant Proteins (4)
Antibodies (4)

By Effects:	Inhibitors (48) Substrates (2) Activators (5)

Art. -Nr.	Produktname	Wirkung	Reinheit	Chemical Structure

HY-15253

Tiplaxtinin	Inhibitor	99.33%
Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC₅₀ of 2.7 μM.

HY-P2373

Kinase, Natto fermentation
Kinase, Natto fermentation is a potent fibrinolytic enzyme. Kinase, Natto fermentation can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Kinase, Natto fermentation can be used for the research of cardiovascular diseases.

HY-B0236

6-Aminocaproic acid	Inhibitor	99.86%
6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders.

HY-101761

TM5441	Inhibitor	99.97%
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1), has IC₅₀ values between 13.9 and 51.1 μM and induces intrinsic apoptosis in several human cancer cell lines. TM5441 attenuates Nω-nitro-l-arginine methyl ester-induced cardiac hypertension and vascular senescence.

HY-P2230

Angstrom6	Inhibitor	99.98%
Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling.

HY-183626

TM5614 sodium	Inhibitor
TM5614 sodium is an orally active and specific PAI-1 inhibitor with an IC₅₀ of <6.95 μM. TM5614 sodium blocks the interaction between PAI-1 and serine proteases or LRP-1, and enhances plasmin generation. TM5614 sodium restores macrophage efferocytosis and promotes macrophage polarization. TM5614 sodium alleviates PAI-1-mediated inhibition of Furin, promotes MT1-MMP maturation, activates the NOTCH1 signaling pathway, inhibits proliferation and induces apoptosis. TM5614 sodium promotes skeletal muscle regeneration and alleviates inflammation in a mouse model of skeletal muscle injury. TM5614 sodium can be used in research on skeletal muscle injury-induced inflammation and chronic myeloid leukemia.

HY-184265

Mito-Esculetin	Inhibitor
Mito-Esculetin (Mito-Esc) is an orally active mitochondria-targeted derivative of Esculetin (HY-N0284). Mito-Esculetin inhibits LPS-induced phosphorylation of STAT3 Tyr-705, partially reverses LPS-mediated depletion of SIRT3, and enhances the AMPK-SIRT1 signaling axis. Mito-Esculetin inhibits PAI-1 activity, regulates miRNA, and induces phosphorylation of IRS and AKT. Mito-Esculetin suppresses oxidant-induced endothelial dysfunction, Ang-II (HY-13948)- and high glucose-induced atherosclerotic plaque formation, Palmitate (HY-N0830)-induced insulin resistance, as well as high glucose-mediated endothelial cell senescence and inflammatory responses. Mito-Esculetin reduces body weight and non-esterified fatty acid (NEFA) levels. Mito-Esculetin can be used in research related to acute coronary syndrome, type 2 diabetes, and hyperglycemia-induced atherosclerosis.

HY-123685

UCD74A (hydrochloride)	Inhibitor
UCD74A hydrochloride is a 5-substituted Amiloride (HY-B0285) analog and urokinase-type plasminogen activator (uPA) inhibitor with an IC₅₀ of 110 μM. UCD74A hydrochloride modulates plasminogen activation cascades linked to extracellular matrix remodeling. UCD74A hydrochloride can be used for the research of tumor metastasis.

HY-14759

Aleplasinin	Inhibitor	99.59%
Aleplastinin (PAZ-417) is an orally active, blood-brain barrier permeable, selective SERPINE1 (PAI-1) inhibitor (IC₅₀=655 nM). Aleplastinin activates the tissue type plasminogen activator (tPA)/fibrinolysis cascade by inhibiting PAI-1, thereby promoting the degradation of amyloid-β (Aβ) oligomers and monomers. Aleplastinin can significantly reduce plasma and brain Aβ levels, improve memory impairment, and reverse cognitive impairment. Aleplastinin can be used for research on Alzheimer's disease.

HY-100447

TM5275 sodium	Inhibitor	98.97%
TM5275 sodium can inhibit the interaction between PAI-1 and LRP1.

HY-132187

Sphingosylphosphorylcholine		99.50%
Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a K_d of 33.3 nM. Sphingosylphosphorylcholine triggers delayed phosphorylation of Smad2, upregulates α-SMA expression, and activates TRPM3. Sphingosylphosphorylcholine reduces Apoptosis and upregulates the expression of uPA and its receptor uPA-R. Sphingosylphosphorylcholine exerts anti-apoptotic, anti-cardiac hypertrophy and pro-wound healing effects. Sphingosylphosphorylcholine induces scratching behavior in mice. Sphingosylphosphorylcholine is used in studies related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and skin wound healing disorders in genetically impaired healing diabetes.

HY-16511

Upamostat		99.02%
Upamostat (WX-671), a prodrug of WX-UK1, is an orally active serine protease inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer.

HY-100415

UKI-1	Inhibitor
UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a K_i of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells.

HY-124577

MDI-2268	Inhibitor	99.73%
MDI-2268 is an inhibitor of plasma kallikrein inhibitor 1 (PAI-1). MDI-2268 has good antithrombotic properties and regulates blood coagulation and fibrinolysis process by enhancing fibrinolysis. MDI-2268 can be used in research areas such as deep vein thrombosis.

HY-N7128

Flavanone	Activator	99.73%
Flavanone is a naturally occurring flavone. Flavanone has inhibitory activity for human estrogen synthetase (aromatase). Flavanone is the inhibitor for ERK/p38/NF-κB signaling pathway. Flavanone exhibits oral activity and antitumor efficacy.

HY-N1504

Loureirin B	Inhibitor	99.96%
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ of 26.10 μM; Loureirin B also inhibits K_ATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.

HY-46749

Muvalaplin tetrahydrochloride		99.55%
Muvalaplin tetrahydrochloride (LY3473329) is an orally active reagent of lipoprotein (a) (Lp (a)). At present, research on Muvalaplin tetrahydrochloride oral reagent is ongoing.

HY-W018723

4-Aminobenzamidine dihydrochloride	Inhibitor	99.97%
4-Aminobenzamidine (p-Aminobenzamidine) dihydrochloride is a strong trypsin inhibitor. 4-Aminobenzamidine dihydrochloride acts as an orally active urokinase type plasminogen activator (uPA) inhibitor (K_i=82 μM). 4-Aminobenzamidine dihydrochloride can be used for cardiovascular diseases and anti-tumor study.

HY-114330A

ZK824859 hydrochloride	Inhibitor	99.03%
ZK824859 hydrochloride is an oral available and selective urokinase plasminogen activator (uPA) inhibitor with IC₅₀s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively.

HY-101214

UK-371804	Inhibitor	98.0%
UK-371804 is a urokinase-type plasminogen activator (uPA) inhibitor with a K_i of 10 nM.

Name
Email *

	Sorry, but the email address you supplied was invalid.

PAI-1

PAI-1

PAI-1 Verwandte Produkte (77)

Recombinant Proteins (4)

Antibodies (4)

PAI-1 Verwandte Produkte (77):